Product Name :
Adalimumab
Description:
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
CAS:
331731-18-1
Molecular Weight:
Formula:
Chemical Name:
Adalimumab
Smiles :
InChiKey:
InChi :
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).|Product information|CAS Number: 331731-18-1|Chemical Name: Adalimumab|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.Oligomycin supplier |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.Dexamethasone phosphate disodium NF-κB |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study.PMID:32936758 |In Vivo:|The elimination half-life (t1/2) of Adalimumab is long (~20 days). The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr-/- mice.|References:| Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97.Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. Products are for research use only. Not for human use.|